{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:25:43Z","timestamp":1785245143225,"version":"3.55.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02048-z","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:53:25Z","timestamp":1771044805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the Fc\u03b3RIIa\u2013Syk\u2013BTK and complement pathways"],"prefix":"10.1007","volume":"26","author":[{"given":"Mahdi","family":"Ahmadinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Askarzade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanif","family":"Afsharara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Gholizadeh Niari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faezeh","family":"Jamali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Farasatinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"2048_CR1","unstructured":"Jinna S, Khandhar PB. Thrombocytopenia [Internet]. StatPearls. 2025. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25134884"},{"key":"2048_CR2","doi-asserted-by":"crossref","unstructured":"Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood [Internet]. 2017;129(21):2829\u201335. Available from: https:\/\/ashpublications.org\/blood\/article\/129\/21\/2829\/36293\/Clinical-updates-in-adult-immune-thrombocytopenia","DOI":"10.1182\/blood-2017-03-754119"},{"key":"2048_CR3","doi-asserted-by":"crossref","unstructured":"Saldanha A, Colella MP, Villa\u00e7a PR, Thachil J, Orsi FA. The immune thrombocytopenia paradox: Should we be concerned about thrombosis in ITP? Thromb Res [Internet]. 2024;241:109109. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482400241X","DOI":"10.1016\/j.thromres.2024.109109"},{"issue":"1","key":"2048_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s42466-025-00374-3","volume":"7","author":"SA Ahmad","year":"2025","unstructured":"Ahmad SA, Liu O, Feng A, Kalra A, Dev A, Spann M, et al. Prevalence and characteristics of acute ischemic stroke and intracranial hemorrhage in patients with immune thrombocytopenic purpura and immune thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Neurol Res Pract. 2025;7(1):19. https:\/\/doi.org\/10.1186\/s42466-025-00374-3.","journal-title":"Neurol Res Pract"},{"key":"2048_CR5","doi-asserted-by":"crossref","unstructured":"Tohidi-Esfahani I, Mittal P, Isenberg D, Cohen H, Efthymiou M. Platelets and Thrombotic Antiphospholipid Syndrome. J Clin Med [Internet]. 2024;13(3):741. Available from: https:\/\/www.mdpi.com\/2077-0383\/13\/3\/741","DOI":"10.3390\/jcm13030741"},{"key":"2048_CR6","doi-asserted-by":"crossref","unstructured":"Clerici B, Scavone M, Podda GM. Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia. Bleeding, Thromb Vasc Biol [Internet]. 2024;3(2). Available from: https:\/\/www.btvb.org\/btvb\/article\/view\/127","DOI":"10.4081\/btvb.2024.127"},{"key":"2048_CR7","doi-asserted-by":"crossref","unstructured":"Hisada R, Kato M, Sugawara E, Fujieda Y, Oku K, Bohgaki T et al. Thrombotic risk stratification by platelet count in patients with antiphospholipid antibodies: a longitudinal study. J Thromb Haemost [Internet]. 2017;15(9):1782\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362200856X","DOI":"10.1111\/jth.13763"},{"key":"2048_CR8","doi-asserted-by":"publisher","unstructured":"Song X, Fan Y, Jia Y, Li G, Liu M, Xu Y et al. A novel aGAPSS-based nomogram for the prediction of ischemic stroke in patients with antiphospholipid syndrome. Front Immunol [Internet]. 2022;13. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2022.930087\/full","DOI":"10.3389\/fimmu.2022.930087\/full"},{"key":"2048_CR9","doi-asserted-by":"crossref","unstructured":"Shi Y, Zhao J, Jiang H, Huang C, Qi W, Song Y et al. Thrombocytopenia in primary antiphospholipid syndrome: association with prognosis and clinical implications. Rheumatology [Internet]. 2022;62(1):256\u201363. Available from: https:\/\/academic.oup.com\/rheumatology\/article\/62\/1\/256\/6583216","DOI":"10.1093\/rheumatology\/keac264"},{"issue":"8","key":"2048_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17474086.2019.1636645","volume":"12","author":"TE Warkentin","year":"2019","unstructured":"Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert Rev Hematol. 2019;12(8):685\u201398. https:\/\/doi.org\/10.1080\/17474086.2019.1636645.","journal-title":"Expert Rev Hematol"},{"key":"2048_CR11","doi-asserted-by":"crossref","unstructured":"Warkentin TE. Autoimmune Heparin-Induced Thrombocytopenia. J Clin Med [Internet]. 2023;12(21):6921. Available from: https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6921","DOI":"10.3390\/jcm12216921"},{"key":"2048_CR12","doi-asserted-by":"crossref","unstructured":"Choi PYI, Uzun G, Bakchoul T. Results of an international survey of opinions on the definitions and treatments for heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost [Internet]. 2024;22(6):1772\u20138. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624000539","DOI":"10.1016\/j.jtha.2024.01.014"},{"issue":"7","key":"2048_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel J, Arnold DM, Grossbard E, Mayer J, Treli\u0144ski J, Homenda W, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921\u201330. https:\/\/doi.org\/10.1002\/ajh.25125.","journal-title":"Am J Hematol"},{"key":"2048_CR14","doi-asserted-by":"publisher","unstructured":"Martinelli I, Abbattista M, Bucciarelli P, Tripodi A, Artoni A, Gianniello F et al. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica [Internet]. 2018;103(7):e315\u20137. Available from: http:\/\/www.haematologica.org\/lookup\/doi\/https:\/\/doi.org\/10.3324\/haematol.2017.185132","DOI":"10.3324\/haematol.2017.185132"},{"key":"2048_CR15","doi-asserted-by":"crossref","unstructured":"Cole MA, Gerber GF, Chaturvedi S. Complement biomarkers in the antiphospholipid syndrome \u2013 Approaches to quantification and implications for clinical management. Clin Immunol [Internet]. 2023;257:109828. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661623005910","DOI":"10.1016\/j.clim.2023.109828"},{"key":"2048_CR16","unstructured":"CISA. U.S. Department of Health and Human Services. 2025 [cited 2025 Aug 27]. Vulnerability Disclosure Policy Template. Available from: https:\/\/www.hhs.gov\/vulnerability-disclosure-policy\/index.html"},{"issue":"3","key":"2048_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1080\/14656566.2024.2328241","volume":"25","author":"L M\u00fcller","year":"2024","unstructured":"M\u00fcller L, Dabbiru VAS, Sch\u00f6nborn L, Greinacher A. Therapeutic strategies in Fc\u03b3IIA receptor-dependent thrombosis and thromboinflammation as seen in heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT). Expert Opin Pharmacother. 2024;25(3):281\u201394. https:\/\/doi.org\/10.1080\/14656566.2024.2328241.","journal-title":"Expert Opin Pharmacother"},{"key":"2048_CR18","doi-asserted-by":"crossref","unstructured":"Kuter DJ, Ghanima W, Cooper N, Liebman HA, Zhang L, Hu Y et al. Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. Blood [Internet]. 2025;145(24):2914\u201326. Available from: https:\/\/ashpublications.org\/blood\/article\/145\/24\/2914\/536104\/Safety-and-efficacy-of-rilzabrutinib-vs-placebo-in","DOI":"10.1182\/blood.2024027336"},{"issue":"15","key":"2048_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1056\/NEJMoa2110297","volume":"386","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ, Efraim M, Mayer J, Trn\u011bn\u00fd M, McDonald V, Bird R, et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med. 2022;386(15):1421\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2110297.","journal-title":"N Engl J Med"},{"key":"2048_CR20","doi-asserted-by":"crossref","unstructured":"Chaturvedi S, Braunstein EM, Brodsky RA. Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications. J Thromb Haemost [Internet]. 2021;19(3):607\u201316. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622006717","DOI":"10.1111\/jth.15082"},{"key":"2048_CR21","doi-asserted-by":"crossref","unstructured":"Dhakal B, Kreuziger LB, Rein L, Kleman A, Fraser R, Aster RH et al. Disease burden, complication rates, and health-care costs of heparin-induced thrombocytopenia in the USA: a population-based study. Lancet Haematol [Internet]. 2018;5(5):e220\u201331. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352302618300462","DOI":"10.1016\/S2352-3026(18)30046-2"},{"key":"2048_CR22","doi-asserted-by":"crossref","unstructured":"Arepally GM, Cines DB. Pathogenesis of heparin-induced thrombocytopenia. Transl Res [Internet]. 2020;225:131\u201340. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931524420300773","DOI":"10.1016\/j.trsl.2020.04.014"},{"key":"2048_CR23","doi-asserted-by":"crossref","unstructured":"Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost [Internet]. 2017;15(11):2099\u2013114. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622043884","DOI":"10.1111\/jth.13813"},{"key":"2048_CR24","doi-asserted-by":"crossref","unstructured":"Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv [Internet]. 2018;2(22):3360\u201392. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/2\/22\/3360\/16129\/American-Society-of-Hematology-2018-guidelines-for","DOI":"10.1182\/bloodadvances.2018024489"},{"key":"2048_CR25","doi-asserted-by":"crossref","unstructured":"Warkentin TE. Platelet-activating anti-PF4 disorders: An overview. Semin Hematol [Internet]. 2022;59(2):59\u201371. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196322000087","DOI":"10.1053\/j.seminhematol.2022.02.005"},{"key":"2048_CR26","doi-asserted-by":"crossref","unstructured":"Leung HHL, Perdomo J, Ahmadi Z, Zheng SS, Rashid FN, Enjeti A et al. NETosis and thrombosis in vaccine-induced immune thrombotic thrombocytopenia. Nat Commun [Internet]. 2022;13(1):5206. Available from: https:\/\/www.nature.com\/articles\/s41467-022-32946-1","DOI":"10.1038\/s41467-022-32946-1"},{"key":"2048_CR27","doi-asserted-by":"crossref","unstructured":"Castelli R, Lambertenghi Delilliers G, Gidaro A, Cicardi M, Bergamaschini L. Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course. Clin Exp Immunol [Internet]. 2020;201(3):258\u201365. Available from: https:\/\/academic.oup.com\/cei\/article\/201\/3\/258\/6403141","DOI":"10.1111\/cei.13475"},{"key":"2048_CR28","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv [Internet]. 2019;3(23):3829\u201366. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/3829\/429213\/American-Society-of-Hematology-2019-guidelines-for"},{"issue":"18","key":"2048_CR29","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.2217\/pgs-2018-0147","volume":"19","author":"JH Karnes","year":"2018","unstructured":"Karnes JH. Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know? Pharmacogenomics. 2018;19(18):1413\u201322. https:\/\/doi.org\/10.2217\/pgs-2018-0147.","journal-title":"Pharmacogenomics"},{"key":"2048_CR30","doi-asserted-by":"publisher","unstructured":"Giles JB, Miller EC, Steiner HE, Karnes JH. Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches. Front Pharmacol [Internet]. 2022;12. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2021.812830\/full","DOI":"10.3389\/fphar.2021.812830\/full"},{"key":"2048_CR31","doi-asserted-by":"crossref","unstructured":"Arepally GM. Heparin-induced thrombocytopenia. Blood [Internet]. 2017;129(21):2864\u201372. Available from: https:\/\/ashpublications.org\/blood\/article\/129\/21\/2864\/36268\/Heparininduced-thrombocytopenia","DOI":"10.1182\/blood-2016-11-709873"},{"key":"2048_CR32","doi-asserted-by":"crossref","unstructured":"Rollin J, Pouplard C, Cheng Sung H, Leroux D, Saada A, Gouilleux-Gruart V et al. Increased risk of thrombosis in Fc\u03b3RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2. Blood [Internet]. 2015;125(15):2397\u2013404. Available from: https:\/\/ashpublications.org\/blood\/article\/125\/15\/2397\/33821\/Increased-risk-of-thrombosis-in-Fc\u03b3RIIA-131RR","DOI":"10.1182\/blood-2014-09-594515"},{"key":"2048_CR33","doi-asserted-by":"crossref","unstructured":"Arman M, Krauel K. Human platelet IgG Fc receptor Fc\u03b3RIIA in immunity and thrombosis. J Thromb Haemost [Internet]. 2015;13(6):893\u2013908. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622127789","DOI":"10.1111\/jth.12905"},{"key":"2048_CR34","doi-asserted-by":"crossref","unstructured":"Sun S, Urbanus RT, ten Cate H, de Groot PG, de Laat B, Heemskerk JWM et al. Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia. Cells [Internet]. 2021;10(12):3386. Available from: https:\/\/www.mdpi.com\/2073-4409\/10\/12\/3386","DOI":"10.3390\/cells10123386"},{"key":"2048_CR35","doi-asserted-by":"crossref","unstructured":"Mititelu A, Onis\u00e2i MC, Ro\u0219ca A, Vl\u0103d\u0103reanu AM. Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. Int J Mol Sci [Internet]. 2024;25(4):2163. Available from: https:\/\/www.mdpi.com\/1422-0067\/25\/4\/2163","DOI":"10.3390\/ijms25042163"},{"key":"2048_CR36","doi-asserted-by":"crossref","unstructured":"Audia S, Mah\u00e9vas M, Samson M, Godeau B, Bonnotte B. Pathogenesis of immune thrombocytopenia. Autoimmun Rev [Internet]. 2017;16(6):620\u201332. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721730109X","DOI":"10.1016\/j.autrev.2017.04.012"},{"issue":"6","key":"2048_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000574","volume":"5","author":"S Audia","year":"2021","unstructured":"Audia S, Mah\u00e9vas M, Nivet M, Ouandji S, Ciudad M, Bonnotte B. Immune thrombocytopenia: recent advances in pathogenesis and treatments. HemaSphere. 2021;5(6):e574. https:\/\/doi.org\/10.1097\/HS9.0000000000000574.","journal-title":"HemaSphere"},{"key":"2048_CR38","doi-asserted-by":"publisher","unstructured":"Yang L, Guo R, Liu H, Chen B, Li C, Liu R et al. Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome. Front Immunol [Internet]. 2025;16. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2025.1527554\/full","DOI":"10.3389\/fimmu.2025.1527554\/full"},{"key":"2048_CR39","doi-asserted-by":"crossref","unstructured":"Prince M, Wenham T. Heparin-induced thrombocytopaenia. Postgrad Med J [Internet]. 2018;94(1114):453\u20137. Available from: https:\/\/academic.oup.com\/pmj\/article\/94\/1114\/453\/6958988","DOI":"10.1136\/postgradmedj-2018-135702"},{"key":"2048_CR40","doi-asserted-by":"crossref","unstructured":"Lee RH, Bergmeier W. Platelet immunoreceptor tyrosine-based activation motif (ITAM) and hemITAM signaling and vascular integrity in inflammation and development. J Thromb Haemost [Internet]. 2016;14(4):645\u201354. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153878362204630X","DOI":"10.1111\/jth.13250"},{"key":"2048_CR41","doi-asserted-by":"crossref","unstructured":"Patel P, Michael JV, Naik UP, McKenzie SE. Platelet Fc\u03b3RIIA in immunity and thrombosis: Adaptive immunothrombosis. J Thromb Haemost [Internet]. 2021;19(5):1149\u201360. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622007462","DOI":"10.1111\/jth.15265"},{"key":"2048_CR42","doi-asserted-by":"crossref","unstructured":"Neeves KB. A tail of two ITAMs: GPVI\/FcR\u03b3 and Fc\u03b3RIIa\u2019s role in platelet activation and thrombus stability. Res Pract Thromb Haemost [Internet]. 2021;5(5):e12564. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792201425X","DOI":"10.1002\/rth2.12564"},{"key":"2048_CR43","doi-asserted-by":"crossref","unstructured":"Durrant TN, van den Bosch MT, Hers I. Integrin \u03b1IIb\u03b23 outside-in signaling. Blood [Internet]. 2017;130(14):1607\u201319. Available from: https:\/\/ashpublications.org\/blood\/article\/130\/14\/1607\/107662\/Integrin-\u03b1IIb\u03b23-outsidein-signaling","DOI":"10.1182\/blood-2017-03-773614"},{"key":"2048_CR44","doi-asserted-by":"crossref","unstructured":"van Rees DJ, Szilagyi K, Kuijpers TW, Matlung HL, van den Berg TK. Immunoreceptors on neutrophils. Semin Immunol [Internet]. 2016;28(2):94\u2013108. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532316000075","DOI":"10.1016\/j.smim.2016.02.004"},{"key":"2048_CR45","doi-asserted-by":"crossref","unstructured":"Tutwiler V, Madeeva D, Ahn HS, Andrianova I, Hayes V, Zheng XL et al. Platelet transactivation by monocytes promotes thrombosis in heparin-induced thrombocytopenia. Blood [Internet]. 2016;127(4):464\u201372. Available from: https:\/\/ashpublications.org\/blood\/article\/127\/4\/464\/35053\/Platelet-transactivation-by-monocytes-promotes","DOI":"10.1182\/blood-2013-11-539262"},{"issue":"1","key":"2048_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/ATVBAHA.120.315445","volume":"41","author":"GM Arepally","year":"2021","unstructured":"Arepally GM, Padmanabhan A. Heparin-induced, thrombocytopenia. Arterioscler Thromb Vasc Biol. 2021;41(1):141\u201352. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315445.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2048_CR47","doi-asserted-by":"crossref","unstructured":"Senis YA, Nagy Z, Mori J, Lane S, Lane P. Platelet Src family kinases: A tale of reversible phosphorylation. Res Pract Thromb Haemost [Internet]. 2021;5(3):376\u201389. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922013462","DOI":"10.1002\/rth2.12495"},{"issue":"3","key":"2048_CR48","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1161\/ATVBAHA.120.315030","volume":"41","author":"RG Xu","year":"2021","unstructured":"Xu RG, Gauer JS, Baker SR, Slater A, Martin EM, McPherson HR, et al. GPVI (Glycoprotein VI) interaction with fibrinogen is mediated by avidity and the fibrinogen \u03b1C-region. Arterioscler Thromb Vasc Biol. 2021;41(3):1092\u2013104. https:\/\/doi.org\/10.1161\/ATVBAHA.120.315030.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2048_CR49","doi-asserted-by":"crossref","unstructured":"Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest [Internet]. 2019;129(1):12\u201323. Available from: https:\/\/www.jci.org\/articles\/view\/122955","DOI":"10.1172\/JCI122955"},{"key":"2048_CR50","doi-asserted-by":"crossref","unstructured":"Ahmed MU, Receveur N, Janus-Bell E, Mouriaux C, Gachet C, Jandrot\u2010Perrus M et al. Respective roles of Glycoprotein VI and Fc\u03b3RIIA in the regulation of \u03b1IIb\u03b23\u2010mediated platelet activation to fibrinogen, thrombus buildup, and stability. Res Pract Thromb Haemost [Internet]. 2021;5(5):e12551. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037922014145","DOI":"10.1002\/rth2.12551"},{"key":"2048_CR51","doi-asserted-by":"crossref","unstructured":"Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood [Internet]. 2019;133(19):2027\u201330. Available from: https:\/\/ashpublications.org\/blood\/article\/133\/19\/2027\/273805\/Fostamatinib-for-the-treatment-of-chronic-immune","DOI":"10.1182\/blood-2018-11-852491"},{"key":"2048_CR52","doi-asserted-by":"crossref","unstructured":"Liu ML, Williams KJ, Werth VP. Microvesicles in Autoimmune Diseases. In. 2016. pp. 125\u201375. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242316300397","DOI":"10.1016\/bs.acc.2016.06.005"},{"key":"2048_CR53","doi-asserted-by":"crossref","unstructured":"Guilliams M, Mildner A, Yona S. Developmental and Functional Heterogeneity of Monocytes. Immunity [Internet]. 2018;49(4):595\u2013613. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761318304461","DOI":"10.1016\/j.immuni.2018.10.005"},{"key":"2048_CR54","doi-asserted-by":"crossref","unstructured":"Audia S, Bonnotte B. Emerging Therapies in Immune Thrombocytopenia. J Clin Med [Internet]. 2021;10(5):1004. Available from: https:\/\/www.mdpi.com\/2077-0383\/10\/5\/1004","DOI":"10.3390\/jcm10051004"},{"key":"2048_CR55","doi-asserted-by":"crossref","unstructured":"Li J, van der Wal DE, Zhu G, Xu M, Yougbare I, Ma L et al. Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia. Nat Commun [Internet]. 2015;6(1):7737. Available from: https:\/\/www.nature.com\/articles\/ncomms8737","DOI":"10.1038\/ncomms8737"},{"key":"2048_CR56","doi-asserted-by":"crossref","unstructured":"Zufferey A, Kapur R, Semple J. Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). J Clin Med [Internet]. 2017;6(2):16. Available from: https:\/\/www.mdpi.com\/2077-0383\/6\/2\/16","DOI":"10.3390\/jcm6020016"},{"key":"2048_CR57","doi-asserted-by":"crossref","unstructured":"Ghanima W, Godeau B, Cines DB, Bussel JB. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood [Internet]. 2012;120(5):960\u20139. Available from: https:\/\/ashpublications.org\/blood\/article\/120\/5\/960\/30278\/How-I-treat-immune-thrombocytopenia-the-choice","DOI":"10.1182\/blood-2011-12-309153"},{"key":"2048_CR58","doi-asserted-by":"publisher","unstructured":"Keragala CB, Draxler DF, McQuilten ZK, Medcalf RL. Haemostasis and innate immunity \u2013 a complementary relationship. Br J Haematol [Internet]. 2018;180(6):782\u201398. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/bjh.15062","DOI":"10.1111\/bjh.15062"},{"key":"2048_CR59","doi-asserted-by":"crossref","unstructured":"Khandelwal S, Barnes A, Rauova L, Sarkar A, Rux AH, Yarovoi SV et al. Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes. Blood [Internet]. 2021;138(21):2106\u201316. Available from: https:\/\/ashpublications.org\/blood\/article\/138\/21\/2106\/476271\/Complement-mediates-binding-and-procoagulant","DOI":"10.1182\/blood.2020009487"},{"key":"2048_CR60","doi-asserted-by":"crossref","unstructured":"Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood [Internet]. 2015;125(21):3253\u201362. Available from: https:\/\/ashpublications.org\/blood\/article\/125\/21\/3253\/34003\/Eculizumab-reduces-complement-activation","DOI":"10.1182\/blood-2014-09-600411"},{"key":"2048_CR61","doi-asserted-by":"crossref","unstructured":"Kasthuri RS, Glover SL, Jonas W, McEachron T, Pawlinski R, Arepally GM et al. PF4\/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of Fc\u03b3RI. Blood [Internet]. 2012;119(22):5285\u201393. Available from: https:\/\/ashpublications.org\/blood\/article\/119\/22\/5285\/105470\/PF4heparinantibody-complex-induces-monocyte-tissue","DOI":"10.1182\/blood-2011-06-359430"},{"key":"2048_CR62","doi-asserted-by":"publisher","unstructured":"Yuen J, Pluthero FG, Douda DN, Riedl M, Cherry A, Ulanova M et al. NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways. Front Immunol [Internet]. 2016;7. Available from: http:\/\/journal.frontiersin.org\/Article\/https:\/\/doi.org\/10.3389\/fimmu.2016.00137\/abstract","DOI":"10.3389\/fimmu.2016.00137\/abstract"},{"key":"2048_CR63","doi-asserted-by":"crossref","unstructured":"Wang H, Wang C, Zhao MH, Chen M. Neutrophil extracellular traps can activate alternative complement pathways. Clin Exp Immunol [Internet]. 2015;181(3):518\u201327. Available from: https:\/\/academic.oup.com\/cei\/article\/181\/3\/518\/6422077","DOI":"10.1111\/cei.12654"},{"issue":"10","key":"2048_CR64","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/art.39239","volume":"67","author":"Y Huang","year":"2015","unstructured":"Huang Y, Wang H, Wang C, Chen M, Zhao M. Promotion of hypercoagulability in antineutrophil cytoplasmic antibody\u2013associated vasculitis by C5a-induced tissue factor\u2013expressing microparticles and neutrophil extracellular traps. Arthritis Rheumatol. 2015;67(10):2780\u201390. https:\/\/doi.org\/10.1002\/art.39239.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2048_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MOH.0000000000000605","volume":"27","author":"S Oncul","year":"2020","unstructured":"Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol. 2020;27(5):341\u201352. https:\/\/doi.org\/10.1097\/MOH.0000000000000605.","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"2048_CR66","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/bjh.13648","volume":"173","author":"EIB Peerschke","year":"2016","unstructured":"Peerschke EIB, Panicker S, Bussel J. Classical complement pathway activation in immune thrombocytopenia purpura: inhibition by a novel C1s inhibitor. Br J Haematol. 2016;173(6):942\u20135. https:\/\/doi.org\/10.1111\/bjh.13648.","journal-title":"Br J Haematol"},{"key":"2048_CR67","doi-asserted-by":"crossref","unstructured":"Reis ES, Mastellos DC, Hajishengallis G, Lambris JD. New insights into the immune functions of complement. Nat Rev Immunol [Internet]. 2019;19(8):503\u201316. Available from: https:\/\/www.nature.com\/articles\/s41577-019-0168-x","DOI":"10.1038\/s41577-019-0168-x"},{"key":"2048_CR68","doi-asserted-by":"crossref","unstructured":"Broome CM, R\u00f6th A, Kuter DJ, Scully M, Smith R, Wang J et al. Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia. Blood Adv [Internet]. 2023;7(6):987\u201396. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/7\/6\/987\/486249\/Safety-and-efficacy-of-classical-complement","DOI":"10.1182\/bloodadvances.2021006864"},{"key":"2048_CR69","doi-asserted-by":"crossref","unstructured":"Behnen M, Leschczyk C, M\u00f6ller S, Batel T, Klinger M, Solbach W et al. Immobilized Immune Complexes Induce Neutrophil Extracellular Trap Release by Human Neutrophil Granulocytes via Fc\u03b3RIIIB and Mac-1. J Immunol [Internet]. 2014;193(4):1954\u201365. Available from: https:\/\/academic.oup.com\/jimmunol\/article\/193\/4\/1954\/7960547","DOI":"10.4049\/jimmunol.1400478"},{"key":"2048_CR70","doi-asserted-by":"crossref","unstructured":"del Conde I, Cr\u00faz MA, Zhang H, L\u00f3pez JA, Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J Exp Med [Internet]. 2005;201(6):871\u20139. Available from: https:\/\/rupress.org\/jem\/article\/201\/6\/871\/52759\/Platelet-activation-leads-to-activation-and","DOI":"10.1084\/jem.20041497"},{"issue":"2","key":"2048_CR71","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1600-0609.2011.01718.x","volume":"88","author":"A Najaoui","year":"2012","unstructured":"Najaoui A, Bakchoul T, Stoy J, Bein G, Rummel MJ, Santoso S, et al. Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol. 2012;88(2):167\u201374. https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01718.x.","journal-title":"Eur J Haematol"},{"issue":"4","key":"2048_CR72","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3324\/haematol.2009.016121","volume":"95","author":"D Helley","year":"2010","unstructured":"Helley D, de Latour RP, Porcher R, Rodrigues CA, Galy-Fauroux I, Matheron J, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2010;95(4):574\u201381. https:\/\/doi.org\/10.3324\/haematol.2009.016121.","journal-title":"Haematologica"},{"key":"2048_CR73","doi-asserted-by":"crossref","unstructured":"Cines DB, Greinacher A. Vaccine-induced immune thrombotic thrombocytopenia. Blood [Internet]. 2023;141(14):1659\u201365. Available from: https:\/\/ashpublications.org\/blood\/article\/141\/14\/1659\/494209\/Vaccine-induced-immune-thrombotic-thrombocytopenia","DOI":"10.1182\/blood.2022017696"},{"key":"2048_CR74","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow B, Warad DM, Jones CG, Pechauer SM, Curtis BR, Bougie DW et al. A prospective, blinded study of a PF4-dependent assay for HIT diagnosis. Blood [Internet]. 2021;137(8):1082\u20139. Available from: https:\/\/ashpublications.org\/blood\/article\/137\/8\/1082\/463714\/A-prospective-blinded-study-of-a-PF4-dependent","DOI":"10.1182\/blood.2020008195"},{"key":"2048_CR75","doi-asserted-by":"crossref","unstructured":"Minet V, Dogn\u00e9 JM, Mullier F. Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review. Molecules [Internet]. 2017;22(4):617. Available from: https:\/\/www.mdpi.com\/1420-3049\/22\/4\/617","DOI":"10.3390\/molecules22040617"},{"key":"2048_CR76","first-page":"861","volume-title":"Platelets","author":"A Michelson","year":"2011","unstructured":"Michelson A. Platelets. Platelets. 2nd ed. Amsterdam, The Netherlands: Elsevier Academic; 2011. pp. 861\u201386.","edition":"2"},{"key":"2048_CR77","doi-asserted-by":"crossref","unstructured":"Jourdi G, Ramstr\u00f6m S, Sharma R, Bakchoul T, Lordkipanidz\u00e9 M. Consensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH. J Thromb Haemost [Internet]. 2023;21(10):2941\u201352. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623005640","DOI":"10.1016\/j.jtha.2023.07.006"},{"key":"2048_CR78","doi-asserted-by":"crossref","unstructured":"Zlamal J, Aliotta A, Alberio L, Chen V, Bakchoul T, Nazy I et al. Diagnostic value of antibody-induced procoagulant platelets in heparin-induced thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost [Internet]. 2024;22(3):860\u20138. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783623008577","DOI":"10.1016\/j.jtha.2023.11.019"},{"key":"2048_CR79","doi-asserted-by":"crossref","unstructured":"Holm S, Kared H, Michelsen AE, Kong XY, Dahl TB, Schultz NH et al. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. Eur Heart J [Internet]. 2021;42(39):4064\u201372. Available from: https:\/\/academic.oup.com\/eurheartj\/article\/42\/39\/4064\/6354117","DOI":"10.1093\/eurheartj\/ehab506"},{"key":"2048_CR80","doi-asserted-by":"crossref","unstructured":"Althaus K, M\u00f6ller P, Uzun G, Singh A, Beck A, Bettag M et al. Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia. Haematologica [Internet]. 2021;106(8):2170\u20139. Available from: https:\/\/haematologica.org\/article\/view\/haematol.2021.279000","DOI":"10.3324\/haematol.2021.279000"},{"key":"2048_CR81","doi-asserted-by":"crossref","unstructured":"Kanack AJ, Bayas A, George G, Abou-Ismail MY, Singh B, Kohlhagen MC et al. Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. Blood [Internet]. 2022;140(1):73\u20137. Available from: https:\/\/ashpublications.org\/blood\/article\/140\/1\/73\/485235\/Monoclonal-and-oligoclonal-anti-platelet-factor-4","DOI":"10.1182\/blood.2021014588"},{"key":"2048_CR82","doi-asserted-by":"crossref","unstructured":"Pitk\u00e4nen HH, Jouppila A, Helin T, Dulipati V, Kotimaa J, Meri S et al. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets. Thromb Res [Internet]. 2021;208:129\u201337. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821005004","DOI":"10.1016\/j.thromres.2021.10.027"},{"key":"2048_CR83","doi-asserted-by":"crossref","unstructured":"Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, Garozzo SF et al. Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica [Internet]. 2021;106(8):2291\u20133. Available from: https:\/\/haematologica.org\/article\/view\/haematol.2021.279075","DOI":"10.3324\/haematol.2021.279075"},{"key":"2048_CR84","doi-asserted-by":"crossref","unstructured":"Nagler M, Bakchoul T. Clinical and laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost [Internet]. 2016;116(11):823\u201334. Available from: http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH16-03-0240","DOI":"10.1160\/TH16-03-0240"},{"key":"2048_CR85","doi-asserted-by":"crossref","unstructured":"Nagler M, Bachmann LM, ten Cate H, ten Cate-Hoek A. Diagnostic value of immunoassays for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood [Internet]. 2016;127(5):546\u201357. Available from: https:\/\/ashpublications.org\/blood\/article\/127\/5\/546\/35100\/Diagnostic-value-of-immunoassays-for","DOI":"10.1182\/blood-2015-07-661215"},{"key":"2048_CR86","doi-asserted-by":"crossref","unstructured":"Reilly-Stitt C, Jennings I, Kitchen S, Makris M, Meijer P, de Maat M et al. Anti\u2010PF4 testing for vaccine\u2010induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. J Thromb Haemost [Internet]. 2022;20(8):1875\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622020785","DOI":"10.1111\/jth.15766"},{"key":"2048_CR87","doi-asserted-by":"crossref","unstructured":"Mali\u010dev E. The use of flow cytometry in the diagnosis of heparin-induced thrombocytopenia (HIT). Transfus Med Rev [Internet]. 2020;34(1):34\u201341. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796319300203","DOI":"10.1016\/j.tmrv.2019.08.001"},{"key":"2048_CR88","doi-asserted-by":"publisher","DOI":"10.1080\/17576180.2024.2373571","author":"M Angeli","year":"2024","unstructured":"Angeli M, Gialeraki A, Anastasopoulou I, Katsarou O, Politou M. Flow cytometry vs conventional methods for the evaluation of anti-PF4\/heparin antibodies: a single center study. Bioanalysis. 2024. https:\/\/doi.org\/10.1080\/17576180.2024.2373571.","journal-title":"Bioanalysis"},{"key":"2048_CR89","doi-asserted-by":"crossref","unstructured":"Zhang Y, Bissola AL, Treverton J, Hack M, Lychacz M, Kwok S et al. Vaccine-Induced Immune Thrombotic Thrombocytopenia: Clinicopathologic Features and New Perspectives on Anti-PF4 Antibody-Mediated Disorders. J Clin Med [Internet]. 2024;13(4):1012. Available from: https:\/\/www.mdpi.com\/2077-0383\/13\/4\/1012","DOI":"10.3390\/jcm13041012"},{"issue":"22","key":"2048_CR90","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","volume":"28","author":"U Swami","year":"2022","unstructured":"Swami U, Graf RP, Nussenzveig RH, Fisher V, Tukachinsky H, Schrock AB, et al. SPOP mutations as a predictive biomarker for androgen receptor axis\u2013targeted therapy in de novo metastatic castration-sensitive prostate cancer. Clin Cancer Res. 2022;28(22):4917\u201325.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2048_CR91","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/tnsci-2020-0206","volume":"12","author":"SR Zhong","year":"2021","unstructured":"Zhong SR, Kuang Q, Zhang F, Chen B, Zhong ZG. Functional roles of the microbiota-gut-brain axis in Alzheimer\u2019s disease: implications of gut microbiota-targeted therapy. Transl Neurosci. 2021;12(1):581\u2013600.","journal-title":"Transl Neurosci"},{"issue":"8","key":"2048_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081793","volume":"13","author":"S Ito","year":"2021","unstructured":"Ito S, Sato T, Maeta T. Role and therapeutic targeting of SDF-1\u03b1\/CXCR4 axis in multiple myeloma. Cancers (Basel). 2021;13(8):1793.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2048_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051103","volume":"13","author":"P von Hundelshausen","year":"2021","unstructured":"von Hundelshausen P, Siess W. Bleeding by Bruton tyrosine kinase-inhibitors: dependency on drug type and disease. Cancers (Basel). 2021;13(5):1103.","journal-title":"Cancers (Basel)"},{"key":"2048_CR94","doi-asserted-by":"crossref","unstructured":"Goldmann L, Duan R, Kragh T, Wittmann G, Weber C, Lorenz R et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (Fc\u03b3RIIA): a new option in HIT? Blood Adv [Internet]. 2019;3(23):4021\u201333. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/3\/23\/4021\/429246\/Oral-Bruton-tyrosine-kinase-inhibitors-block","DOI":"10.1182\/bloodadvances.2019000617"},{"issue":"16Supplement","key":"2048_CR95","volume":"80","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhao R, Liang R, Gao Y, Liu R, Chen X, et al. Abstract CT132: orelabrutinib, a potent and selective bruton\u2019s tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties. Cancer Res. 2020;80(16Supplement):CT132\u2013132.","journal-title":"Cancer Res"},{"key":"2048_CR96","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1182\/blood-2021-144691","volume":"138","author":"T Yu","year":"2021","unstructured":"Yu T, Wang L, Ni X, Hou Y, Liu X, Hou M. Orelabrutinib, a selective Bruton\u2019s tyrosine kinase (BTK) inhibitor in the treatment of primary immune thrombocytopenia (ITP). Blood. 2021;138:3172.","journal-title":"Blood"},{"issue":"7","key":"2048_CR97","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","volume":"206","author":"CL Langrish","year":"2021","unstructured":"Langrish CL, Bradshaw JM, Francesco MR, Owens TD, Xing Y, Shu J, et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J Immunol. 2021;206(7):1454\u201368.","journal-title":"J Immunol"},{"key":"2048_CR98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122336","volume":"134","author":"DJ Kuter","year":"2019","unstructured":"Kuter DJ, Boccia RV, Lee EJ, Efraim M, Tzvetkov N, Mayer J, et al. Phase I\/II, open-label, adaptive study of oral bruton tyrosine kinase inhibitor PRN1008 in patients with relapsed\/refractory primary or secondary immune thrombocytopenia. Blood. 2019;134:87.","journal-title":"Blood"},{"key":"2048_CR99","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2016-07-726901","volume":"130","author":"CL Langrish","year":"2017","unstructured":"Langrish CL, Bradshaw JM, Owens TD, Campbell RL, Francesco MR, Karr DE, et al. PRN1008, a reversible covalent BTK inhibitor in clinical development for immune thrombocytopenic purpura. Blood. 2017;130:1052.","journal-title":"Blood"},{"issue":"4","key":"2048_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24040809","volume":"24","author":"BG de la Torre","year":"2019","unstructured":"de la Torre BG, Albericio F. The pharmaceutical industry in 2018. an analysis of FDA drug approvals from the perspective of molecules. Molecules. 2019;24(4):809.","journal-title":"Molecules"},{"issue":"18","key":"2048_CR101","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.2217\/imt-2020-0215","volume":"12","author":"A Newland","year":"2020","unstructured":"Newland A, McDonald V. Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Immunotherapy. 2020;12(18):1325\u201340.","journal-title":"Immunotherapy"},{"issue":"1\u20133","key":"2048_CR102","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17474086.2024.2318345","volume":"17","author":"D Provan","year":"2024","unstructured":"Provan D, Thachil J, \u00c1lvarez Rom\u00e1n MT. Addressing thrombosis concerns in immune thrombocytopenia: the role of fostamatinib in immune thrombocytopenia management. Expert Rev Hematol. 2024;17(1\u20133):55\u201366.","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"2048_CR103","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1538-7836.2009.03451.x","volume":"7","author":"JC Spalton","year":"2009","unstructured":"Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP. The novel syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets. J Thromb Haemost. 2009;7(7):1192\u20139.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"2048_CR104","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1111\/j.1538-7836.2011.04470.x","volume":"9","author":"T Lhermusier","year":"2011","unstructured":"Lhermusier T, Van Rottem J, Garcia C, Xuereb J, Ragab A, Martin V, et al. The syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin\u2010PF4 complex directed antibodies. J Thromb Haemost. 2011;9(10):2067\u201376.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2048_CR105","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/bjh.19070","volume":"203","author":"IC Weitz","year":"2023","unstructured":"Weitz IC, Liebman HA. Complement in immune thrombocytopenia (ITP): the role of complement in refractory ITP. Br J Haematol. 2023;203(1):96\u2013100. https:\/\/doi.org\/10.1111\/bjh.19070.","journal-title":"Br J Haematol"},{"key":"2048_CR106","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1182\/blood-2020-139663","volume":"136","author":"CM Broome","year":"2020","unstructured":"Broome CM, R\u00f6th A, Kuter DJ, Scully M, Smith R, Wang J, et al. Long-term safety and efficacy of sutimlimab in patients with chronic immune thrombocytopenia. Blood. 2020;136:14\u20135.","journal-title":"Blood"},{"key":"2048_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","volume":"12","author":"GE Ringheim","year":"2021","unstructured":"Ringheim GE, Wampole M, Oberoi K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front Immunol. 2021;12:662223.","journal-title":"Front Immunol"},{"issue":"1","key":"2048_CR108","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jox13010005","volume":"13","author":"MA Ali","year":"2023","unstructured":"Ali MA, Anwar MY, Aiman W, Dhanesar G, Omar Z, Hamza M, et al. Safety and efficacy of tyrosine kinase inhibitors in immune thrombocytopenic purpura: a systematic review of clinical trials. J Xenobiotics. 2023;13(1):29\u201341.","journal-title":"J Xenobiotics"},{"issue":"1","key":"2048_CR109","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","volume":"10","author":"J Perdomo","year":"2019","unstructured":"Perdomo J, Leung HHL, Ahmadi Z, Yan F, Chong JJH, Passam FH, et al. Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia. Nat Commun. 2019;10(1):1322.","journal-title":"Nat Commun"},{"issue":"3","key":"2048_CR110","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13543784.2022.2040014","volume":"31","author":"S Tang","year":"2022","unstructured":"Tang S, Yu Q, Ding C. Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases. Expert Opin Investig Drugs. 2022;31(3):291\u2013303.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2048_CR111","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2022.2131751","volume":"34","author":"N Cooper","year":"2023","unstructured":"Cooper N, Ghanima W, Hill QA, Nicolson PLR, Markovtsov V, Kessler C. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets. 2023;34(1):2131751.","journal-title":"Platelets"},{"key":"2048_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00078","volume":"7","author":"GM Deng","year":"2016","unstructured":"Deng GM, Kyttaris VC, Tsokos GC. Targeting syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78.","journal-title":"Front Immunol"},{"issue":"1","key":"2048_CR113","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2217\/imt-2017-0097","volume":"10","author":"A Newland","year":"2018","unstructured":"Newland A, Lee EJ, McDonald V, Bussel JB. Fostamatinib for persistent\/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9\u201325.","journal-title":"Immunotherapy"},{"issue":"6","key":"2048_CR114","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","volume":"36","author":"JMM van Eeuwijk","year":"2016","unstructured":"van Eeuwijk JMM, Stegner D, Lamb DJ, Kraft P, Beck S, Thielmann I, et al. The novel oral syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infarction. Arterioscler Thromb Vasc Biol. 2016;36(6):1247\u201353.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2048_CR115","doi-asserted-by":"crossref","unstructured":"Zheng Y, Zhu W, Haribhai D, Williams CB, Aster RH, Wen R et al. Regulatory T Cells Control PF4\/Heparin Antibody Production in Mice. J Immunol [Internet]. 2019;203(7):1786\u201392. Available from: https:\/\/academic.oup.com\/jimmunol\/article\/203\/7\/1786\/7952294","DOI":"10.4049\/jimmunol.1900196"},{"key":"2048_CR116","unstructured":"Blank M, Eldor A, Tavor S, Ziporen L, Cines DB, Arepally G et al. A mouse model for heparin-induced thrombocytopenia. Semin Hematol [Internet]. 1999;36(1 Suppl 1):12\u20136. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9930558"},{"issue":"2","key":"2048_CR117","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/ajh.25680","volume":"95","author":"AC Newland","year":"2020","unstructured":"Newland AC, S\u00e1nchez-Gonz\u00e1lez B, Rejt\u0151 L, Egyed M, Romanyuk N, Godar M, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178\u201387. https:\/\/doi.org\/10.1002\/ajh.25680.","journal-title":"Am J Hematol"},{"issue":"11","key":"2048_CR118","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019;134(11):851\u20139.","journal-title":"Blood"},{"issue":"Suppl","key":"2048_CR119","doi-asserted-by":"publisher","first-page":"e67955a3","DOI":"10.1097\/01.HS9.0000973288.67955.a3","volume":"7","author":"QS Huang","year":"2023","unstructured":"Huang QS, Fu HX, Wang CC, Zhu XL, He Y, Chen Q, et al. P1603: efficacy and safety of bruton\u2019s tyrosine kinase inhibitor zanubrutinib in ITP. HemaSphere. 2023;7(Suppl):e67955a3.","journal-title":"HemaSphere"},{"issue":"2","key":"2048_CR120","first-page":"e70152","volume":"8","author":"B Ding","year":"2025","unstructured":"Ding B, Li M, Liu L, Song X, Zhang Y, Xia A, et al. A case series and literature review on zanubrutinib therapy for the treatment of Relapsed\/Refractory immune thrombocytopenia. Cancer Rep. 2025;8(2):e70152.","journal-title":"Cancer Rep"},{"issue":"3","key":"2048_CR121","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/ajh.27539","volume":"100","author":"N Cooper","year":"2025","unstructured":"Cooper N, Jansen AJG, Bird R, Mayer J, Sholzberg M, Tarantino MD, et al. Efficacy and safety results with rilzabrutinib, an oral bruton tyrosine kinase inhibitor, in patients with immune thrombocytopenia: phase 2 part B study. Am J Hematol. 2025;100(3):439\u201349.","journal-title":"Am J Hematol"},{"issue":"6","key":"2048_CR122","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/blood.2024024250","volume":"144","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2024","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Bermejo-Vega N, Cardesa-Cabrera R, Mart\u00ednez-Robles V, Aguilar-Monserrate G, P\u00e9rez-Segura G, et al. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood. 2024;144(6):646\u201356.","journal-title":"Blood"},{"key":"2048_CR123","doi-asserted-by":"crossref","unstructured":"Li M, Liu L, Ding B, Xia A, Han Y, Song X et al. Refractory\/relapse thrombocytopenia in a patient with evans\u2019 syndrome successfully treated with zanubrutinib. 2022.","DOI":"10.21203\/rs.3.rs-1540326\/v1"},{"issue":"7","key":"2048_CR124","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1182\/bloodadvances.2023012044","volume":"8","author":"DJ Kuter","year":"2024","unstructured":"Kuter DJ, Mayer J, Efraim M, Bogdanov LH, Baker R, Kaplan Z, et al. Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. Blood Adv. 2024;8(7):1715\u201324.","journal-title":"Blood Adv"},{"issue":"6","key":"2048_CR125","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","volume":"10","author":"X Liu","year":"2023","unstructured":"Liu X, Zhou H, Hu Y, Yin J, Li J, Chen W, et al. Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in china: a randomised, double-blind, placebo-controlled, phase 1b\/2 study. Lancet Haematol. 2023;10(6):e406\u201318.","journal-title":"Lancet Haematol"},{"key":"2048_CR126","doi-asserted-by":"crossref","unstructured":"Pellegrini L, Novak U, Andres M, \u2026 TSCR in, 2021 undefined. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: a systematic review and meta-analysis. ElsevierL Pellegrini, U Novak, M Andres, T Suter, M NaglerCritical Rev Oncol 2021\u2022Elsevier.","DOI":"10.1016\/j.critrevonc.2021.103238"},{"issue":"6","key":"2048_CR127","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1080\/10428194.2023.2199341","volume":"64","author":"D Allsup","year":"2023","unstructured":"Allsup D, Molica S. Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report. Leuk Lymphoma. 2023;64(6):1216\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2048_CR128","first-page":"1","volume":"13","author":"CS Tam","year":"2023","unstructured":"Tam CS, Mu\u00f1oz JL, Seymour JF, Opat S. Zanubrutinib: past, present, and future. Blood Cancer J. 2023;13(1):1\u201313.","journal-title":"Blood Cancer J"},{"key":"2048_CR129","doi-asserted-by":"crossref","unstructured":"Varettoni M, Clinics JVMH. 2023 undefined. BTK inhibitors in the frontline management of waldenstr\u00f6m macroglobulinemia. iwmf.comM Varettoni, JV MatousHematology\/Oncology Clin 2023\u2022iwmf.com.","DOI":"10.1016\/j.hoc.2023.04.005"},{"key":"2048_CR130","unstructured":"Orelabrutinib Receives. Breakthrough Therapy Designation for Mantle Cell Lymphoma. 2021."},{"key":"2048_CR131","first-page":"8161","volume":"19","author":"L Liu","year":"2025","unstructured":"Liu L, Xiao Y, Jia Y, Shao Z, Shi J, Cui C, Xiao Y, Jia Y, Shao Z, Shi J. C Cuid Des Dev Ther 2025\u2022Taylor Fr. 2025;19:8161\u201380.","journal-title":"C Cuid Des Dev Ther 2025\u2022Taylor Fr"},{"key":"2048_CR132","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00675-9","author":"B Aslan","year":"2022","unstructured":"Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, et al. Pirtobrutinib inhibits wild-type and mutant Bruton\u2019s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022. https:\/\/doi.org\/10.1038\/s41408-022-00675-9.","journal-title":"Blood Cancer J"},{"key":"2048_CR133","unstructured":"Mehra S, Nicholls M, Molecular JTIJ of, Nicholls M. J TaylorInternational J Mol Sci 2024\u2022mdpi.com."},{"key":"2048_CR134","unstructured":"Frustaci A, Deodato M, Zamprogna G, Cancers RC, Deodato M, Zamprogna G, Cairoli R, Montillo M. A TedeschiCancers, 2023\u2022mdpi.com."},{"key":"2048_CR135","unstructured":"Study Details |. NCT05279872 | A Study of Zanubrutinib in Patients With ITP | ClinicalTrials.gov."},{"key":"2048_CR136","unstructured":"Study Details. | NCT05214391 | A Prospective, One-arm and open clinical study of zanubrutinib in the treatment of Immune Thrombocytopenia | ClinicalTrials.gov."},{"key":"2048_CR137","unstructured":"Study Details. | NCT07007962 | study to evaluate the efficacy and safety of oral Rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed First-line Treatment | ClinicalTrials.gov."},{"issue":"12","key":"2048_CR138","doi-asserted-by":"publisher","first-page":"7907","DOI":"10.1097\/MS9.0000000000004164","volume":"87","author":"SFZ Hujjat","year":"2025","unstructured":"Hujjat SFZ, Chandani HK, Khan MS, Chandani DK, Mahmoud A. Bruton\u2019s tyrosine kinase inhibition in ITP: wayrilz (rilzabrutinib) as a disease-modifying strategy. Ann Med Surg. 2025;87(12):7907\u20139. https:\/\/doi.org\/10.1097\/MS9.0000000000004164.","journal-title":"Ann Med Surg"},{"key":"2048_CR139","doi-asserted-by":"crossref","unstructured":"Gelarden IA, Richardson AI. A 1-year-old child with essential thrombocythemia. Blood [Internet]. 2024;144(1):122\u2013122. Available from: https:\/\/ashpublications.org\/blood\/article\/144\/1\/122\/516725\/A-1-year-old-child-with-essential-thrombocythemia","DOI":"10.1182\/blood.2024024479"},{"issue":"8","key":"2048_CR140","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/ajh.27718","volume":"100","author":"Q Huang","year":"2025","unstructured":"Huang Q, Fu H, Wang C, Zhu X, He Y, Wu J, et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor zanubrutinib in immune thrombocytopenia. Am J Hematol. 2025;100(8):1314\u201322. https:\/\/doi.org\/10.1002\/ajh.27718.","journal-title":"Am J Hematol"},{"key":"2048_CR141","unstructured":"Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, Stefano V et al. G GaidanoBritish J Haematol 2025\u2022Wiley Online Libr. 2025."},{"key":"2048_CR142","unstructured":"Study Details. | NCT04904276 | observational study of fostamatinib as second line therapy in adult patients with immune thrombocytopenia (ITP) and insufficient response to a Prior Therapy | ClinicalTrials.gov."},{"issue":"6","key":"2048_CR143","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.18582","volume":"200","author":"M Kuwana","year":"2023","unstructured":"Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, et al. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double\u2010blind, parallel\u2010group study. Br J Haematol. 2023;200(6):802\u201311.","journal-title":"Br J Haematol"},{"issue":"3","key":"2048_CR144","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s12185-025-03924-2","volume":"121","author":"M Kuwana","year":"2025","unstructured":"Kuwana M, Tomiyama Y. Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia. Int J Hematol. 2025;121(3):356\u201362.","journal-title":"Int J Hematol"},{"key":"2048_CR145","unstructured":"Study Details | NCT04056195 | Study of Oral SKI-O-703, Inhibitor SYK. in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) | ClinicalTrials.gov."},{"key":"2048_CR146","unstructured":"Study Details. | NCT05029635 | phase III study on HMPL-523 for treatment of ITP | ClinicalTrials.gov."},{"key":"2048_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109629","volume":"251","author":"KT Simmons","year":"2023","unstructured":"Simmons KT, Chan J, Hussain S, Rose EL, Markham K, Byun TS, et al. Anti-C1s humanized monoclonal antibody SAR445088: a classical pathway complement inhibitor specific for the active form of C1s. Clin Immunol. 2023;251:109629.","journal-title":"Clin Immunol"},{"issue":"23","key":"2048_CR148","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1182\/blood.V126.23.2253.2253","volume":"126","author":"EE Roesch","year":"2015","unstructured":"Roesch EE, Broome C. Complement blockade with C1 esterase inhibitor in refractory immune thrombocytopenia. Blood. 2015;126(23):2253.","journal-title":"Blood"},{"issue":"7","key":"2048_CR149","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"key":"2048_CR150","unstructured":"Study Details | NCT04562766 |. Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP) | ClinicalTrials.gov."},{"issue":"7","key":"2048_CR151","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1002\/ajh.27303","volume":"99","author":"S Yan","year":"2024","unstructured":"Yan S, Zhou H, Huang R, Wang F, Mei H, Lin L, et al. A phase 2 trial of orelabrutinib showing promising efficacy and safety in patients with persistent or chronic primary immune thrombocytopenia. Am J Hematol. 2024;99(7):1392\u20135.","journal-title":"Am J Hematol"},{"key":"2048_CR152","unstructured":"Study, Details. | NCT02076399 | A efficacy and safety study of R935788 in the treatment of Persistent\/Chronic immune thrombocytopenic purpura (ITP) | ClinicalTrials.gov."},{"key":"2048_CR153","unstructured":"Study Details. | NCT02077192 | open label study of R788 in the treatment of Persistent\/Chronic immune thrombocytopenic purpura (ITP) | ClinicalTrials.gov."},{"key":"2048_CR154","doi-asserted-by":"crossref","unstructured":"Cooper N, Altomare I, Thomas MR, Nicolson PLR, Watson SP, Markovtsov V, Cooper I, Altomare MR, Thomas PLR, Nicolson SP, Watson V, Markovtsov et al. LK ToddTherapeutic Adv Hematol 2021\u2022journals.sagepub.com. 2021;12.","DOI":"10.1177\/20406207211010875"},{"issue":"5","key":"2048_CR155","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ajh.25444","volume":"94","author":"JB Bussel","year":"2019","unstructured":"Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, et al. Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program. Am J Hematol. 2019;94(5):546\u201353.","journal-title":"Am J Hematol"},{"issue":"8","key":"2048_CR156","doi-asserted-by":"publisher","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","volume":"11","author":"Y Hu","year":"2024","unstructured":"Hu Y, Liu X, Zhou H, Wang S, Huang R, Wang Y, et al. Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Haematol. 2024;11(8):e567\u201379.","journal-title":"Lancet Haematol"},{"key":"2048_CR157","unstructured":"Study Details. | NCT05132127 | Sutimlimab (BIVV009) for the adult participants with cold agglutinin disease (CAD) who have completed phase 3 studies (CARDINAL or CADENZA) in Japan | ClinicalTrials.gov."},{"key":"2048_CR158","unstructured":"Study Details. | NCT04669600 | A phase 2a study evaluating BIVV020 in adults with Persistent\/Chronic immune thrombocytopenia (ITP) | ClinicalTrials.gov."},{"key":"2048_CR159","unstructured":"Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet [Internet]. 2023;402(10413):1648\u201359. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673623014605"},{"key":"2048_CR160","doi-asserted-by":"crossref","unstructured":"Warkentin TE. Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review. Res Pract Thromb Haemost [Internet]. 2023;7(8):102245. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923056686","DOI":"10.1016\/j.rpth.2023.102245"},{"key":"2048_CR161","doi-asserted-by":"publisher","unstructured":"Yun Z, Duan L, Liu X, Cai Q, Li C. An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol [Internet]. 2023;14. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2023.1145145\/full","DOI":"10.3389\/fimmu.2023.1145145\/full"},{"key":"2048_CR162","doi-asserted-by":"crossref","unstructured":"Hussain H, Tarantino MD, Chaturvedi S, McCrae KR, Roberts JC. Eculizumab for refractory thrombosis in antiphospholipid syndrome. Blood Adv [Internet]. 2022;6(4):1271\u20137. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/6\/4\/1271\/483611\/Eculizumab-for-refractory-thrombosis-in","DOI":"10.1182\/bloodadvances.2021005657"},{"issue":"2","key":"2048_CR163","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1060028020943542","volume":"55","author":"JA Dougherty","year":"2021","unstructured":"Dougherty JA, Yarsley RL. Intravenous immune globulin (IVIG) for treatment of autoimmune heparin-induced thrombocytopenia: a systematic review. Ann Pharmacother. 2021;55(2):198\u2013215. https:\/\/doi.org\/10.1177\/1060028020943542.","journal-title":"Ann Pharmacother"},{"key":"2048_CR164","doi-asserted-by":"crossref","unstructured":"Kanack AJ, Athale J, Leger RR, Saadalla A, Heikal NM, Chen D et al. Autoimmune HIT antibodies in diagnostic samples are a potential artifact and not associated with more severe outcomes. Blood Adv [Internet]. 2023;7(16):4431\u20134. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4431\/496130\/Autoimmune-HIT-antibodies-in-diagnostic-samples","DOI":"10.1182\/bloodadvances.2023009811"},{"key":"2048_CR165","doi-asserted-by":"crossref","unstructured":"Greinacher A, Warkentin TE. Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond. Hematology [Internet]. 2023;2023(1):1\u201310. Available from: https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/1\/506391\/Thrombotic-anti-PF4-immune-disorders-HIT-VITT-and","DOI":"10.1182\/hematology.2023000503"},{"key":"2048_CR166","doi-asserted-by":"crossref","unstructured":"Padmanabhan A, Jones CG, Bougie DW, Curtis BR, McFarland JG, Wang D et al. Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis. Blood [Internet]. 2015;125(1):155\u201361. Available from: https:\/\/ashpublications.org\/blood\/article\/125\/1\/155\/33917\/Heparinindependent-PF4dependent-binding-of-HIT","DOI":"10.1182\/blood-2014-06-580894"},{"key":"2048_CR167","doi-asserted-by":"crossref","unstructured":"Yeung J, Tourdot BE, Fernandez-Perez P, Vesci J, Ren J, Smyrniotis CJ et al. Platelet 12-LOX is essential for Fc\u03b3RIIa-mediated platelet activation. Blood [Internet]. 2014;124(14):2271\u20139. Available from: https:\/\/ashpublications.org\/blood\/article\/124\/14\/2271\/33109\/Platelet-12LOX-is-essential-for-Fc\u03b3RIIamediated","DOI":"10.1182\/blood-2014-05-575878"},{"key":"2048_CR168","doi-asserted-by":"publisher","unstructured":"Perova T, Grandal I, Nutter LMJ, Papp E, Matei IR, Beyene J et al. Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia. Sci Transl Med [Internet]. 2014;6(236). Available from: https:\/\/www.science.org\/doi\/https:\/\/doi.org\/10.1126\/scitranslmed.3008661","DOI":"10.1126\/scitranslmed.3008661"},{"key":"2048_CR169","doi-asserted-by":"crossref","unstructured":"Harishkumar R, Hans S, Stanton JE, Grabrucker AM, Lordan R, Zabetakis I. Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients. Nutrients [Internet]. 2022;14(20):4414. Available from: https:\/\/www.mdpi.com\/2072-6643\/14\/20\/4414","DOI":"10.3390\/nu14204414"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02048-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02048-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:03:41Z","timestamp":1771337021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02048-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":169,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02048-z","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,14]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a narrative review and did not involve any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Clinical trial registration: Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}